Seattle Genetics Hoping Adcetris Label Expansion Trials Can Be Confirmatory

Over the next six weeks Seattle Genetics intends to negotiate with FDA over its plans for confirmatory trials to support accelerated approval of Adcetris (brentuximab vedotin) – which the company hopes to accomplish using studies already planned as further development of the antibody-drug conjugate.